No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TSHA Taysha Gene Therapies
- 2.3900
- +0.0900+3.91%
Close Apr 26 16:00 ET
- 2.3513
- -0.0387-1.62%
Post 18:00 ET
446.97MMarket Cap-2489P/E (TTM)
2.4500High2.2950Low890.19KVolume2.3500Open2.3000Pre Close2.14MTurnover0.89%Turnover RatioLossP/E (Static)187.02MShares3.890052wk High5.96P/B239.25MFloat Cap0.500052wk Low--Dividend TTM100.10MShs Float33.3500Historical High--Div YieldTTM6.74%Amplitude0.5000Historical Low2.4000Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
Express News | Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today's pre-market trading after
Express News | Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Impact and Outlook: Taysha Gene Therapies Stock Analysis
Comments
Felt like sharing after I read! Enjoy! Hehehe
$Taysha Gene Therapies(TSHA.US$ Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
3
Despite Taysha Gene Therapies' share price surge, its high P/S ratio amidst declining future revenues and a growing industry is worrisome. Investors should remain cautious due to the predicted future revenue decline.
Gene Therapy Company Reports Remarkable 2023 Financial Results
Taysha Gene Therapies: A Beacon of Hope in Gene Therapy Innovation.
In a recent groundbreaking announcement, Taysha Gene Therapies has unveiled its full-year financial results for 2023, alongside significant corporate and clinical updates that have captivated the biotechnology and healthcare sectors. As a pivotal player in the arena of gene therapy, Taysha's latest disclosures are not just numbers on a balance sheet; they represent a ...
In a recent groundbreaking announcement, Taysha Gene Therapies has unveiled its full-year financial results for 2023, alongside significant corporate and clinical updates that have captivated the biotechnology and healthcare sectors. As a pivotal player in the arena of gene therapy, Taysha's latest disclosures are not just numbers on a balance sheet; they represent a ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg